Sort   by:  
 Page size 
UnknownBortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Not available
S-EPMC3577952 | biostudies-literature
UnknownClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.
Not available
S-EPMC3731981 | biostudies-literature
UnknownAge-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
Not available
S-EPMC3295550 | biostudies-literature
UnknownEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
Not available
S-EPMC3918538 | biostudies-literature
UnknownSafety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Not available
S-EPMC11795396 | biostudies-literature
UnknownEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Not available
S-EPMC7787219 | biostudies-literature
Sort   by:  
 Page size